NanoViricides Inc (NNVC)-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8013554)
◆英語タイトル:NanoViricides Inc (NNVC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013554
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:45
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥26,250見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥52,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥78,750見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
NanoViricides Inc (NanoViricides), formerly Edot-com.com Inc is a biopharmaceutical company that provides nanomedicine technology solutions. The company conducts research in the areas of medical science and pharmaceutical technology such as polymeric micelles, multi-specific multi-targeting, anti-sense DNA, siRNA, ribozymes and gene therapy. It offers pipeline product portfolio such as drugs for various indications such as HIV, influenza, flaviviruses including dengue and eye drops, among others. The company develops drugs against various viral diseases including H5N1 bird flu, seasonal influenza, HIV, epidemic kerato-conjunctivitis, hepatitis C, rabies, dengue fever and Ebola virus, among others. NanoViricides is headquartered in Shelton, Connecticut, the US.

NanoViricides Inc (NNVC) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
NanoViricides Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
NanoViricides Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
NanoViricides Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
NanoViricides Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
NanoViricides Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
NanoViricides Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
NanoViricides Enters into Agreement with SUNY Upstate Medical University 10
NanoViricides Enters into Agreement with St. Jude Children’s Research Hospital 11
NanoViricides Enters into Agreement with Baylor College of Medicine 12
NanoViricides Enters into Research Agreement with University of Pittsburgh 13
NanoViricides Enters into Agreement with University of Wisconsin-Madison 14
Equity Offering 15
NanoViricides Raises USD7.5 Million in Private Placement of Shares upon Exercise of Warrants 15
NanoViricides Completes Private Placement Of Units For US$20 Million 16
NanoViricides Completes Public Offering Of Units For US$10.3 Million 18
NanoViricides Completes Final Tranche Of Private Placement Of Series C Preferred Stock For US$2.5 Million 19
NanoViricides Files Shelf Registration Statement For Public Offering Of Securities For US$40 Million 21
Nanoviricides Completes Final Tranche Of Private Placement Of Series B Convertible Preferred Stock For US$2.5 Million 22
NanoViricides Completes Second Tranche Of Private Placement Of Series B Preferred Stock For US$2.5 Million 24
Debt Offering 26
NanoViricides Completes Private Placement Of Debentures Due 2017 For US$6 Million 26
NanoViricides Inc – Key Competitors 27
NanoViricides Inc – Key Employees 28
NanoViricides Inc – Locations And Subsidiaries 29
Head Office 29
Recent Developments 30
Financial Announcements 30
Nov 20, 2017: NanoViricides Files Quarterly Report for Period Ending September 30, 2017 30
May 16, 2017: NanoViricides Files Quarterly Report for Period Ending 2017-03-31 31
Feb 16, 2017: NanoViricides Files Quarterly Report for Period Ending 2016-12-31 33
May 11, 2016: NanoViricides Files Quarterly Report for Period Ending 2016-03-31 35
Feb 10, 2016: NanoViricides Files Quarterly Report for Period Ending 2015-12-31 37
Product News 39
11/06/2017: NanoViricides Provides Further Details on Its Herpes-Induced Acute Retinal Necrosis Animal Study to be Presented On November 10th at the Annual Meeting of the Ocular Microbiology and Immunology Group of the American Academy of Ophthalmology 39
Jun 20, 2016: NanoViricides Reports On Progress of Its Drug Candidates against Herpesviruses 40
06/06/2017: NanoViricides Reports Excellent Inhibitory Effects of Its Topical Shingles Treatment Candidates Against VZV in Multiple Cell Culture Studies 41
01/12/2016: NanoViricides CEO Dr. Eugene Seymour to Present at the Biotech Showcase in San Fransisco on Wednesday 42
Other Significant Developments 43
Nov 15, 2016: NanoViricides Files Quarterly Report for Period Ending 2016-09-30 43
Appendix 45
Methodology 45
About GlobalData 45
Contact Us 45
Disclaimer 45

List of Tables
NanoViricides Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
NanoViricides Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
NanoViricides Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
NanoViricides Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
NanoViricides Inc, Deals By Therapy Area, 2011 to YTD 2017 8
NanoViricides Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
NanoViricides Enters into Agreement with SUNY Upstate Medical University 10
NanoViricides Enters into Agreement with St. Jude Children's Research Hospital 11
NanoViricides Enters into Agreement with Baylor College of Medicine 12
NanoViricides Enters into Research Agreement with University of Pittsburgh 13
NanoViricides Enters into Agreement with University of Wisconsin-Madison 14
NanoViricides Raises USD7.5 Million in Private Placement of Shares upon Exercise of Warrants 15
NanoViricides Completes Private Placement Of Units For US$20 Million 16
NanoViricides Completes Public Offering Of Units For US$10.3 Million 18
NanoViricides Completes Final Tranche Of Private Placement Of Series C Preferred Stock For US$2.5 Million 19
NanoViricides Files Shelf Registration Statement For Public Offering Of Securities For US$40 Million 21
Nanoviricides Completes Final Tranche Of Private Placement Of Series B Convertible Preferred Stock For US$2.5 Million 22
NanoViricides Completes Second Tranche Of Private Placement Of Series B Preferred Stock For US$2.5 Million 24
NanoViricides Completes Private Placement Of Debentures Due 2017 For US$6 Million 26
NanoViricides Inc, Key Competitors 27
NanoViricides Inc, Key Employees 28

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ NanoViricides Inc (NNVC)-製薬・医療分野:企業M&A・提携分析(NanoViricides Inc (NNVC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆